Nature's Elements sold supplement powders with disease claims as unapproved drugs and made them with no required manufacturing records, FDA says.
What happened
FDA inspected the company's Bohemia, New York facility on October 14-16, 2025, and also reviewed product labels collected there and the website www.natureselements.net between October and December 2025. The inspection found the firm had not set finished-product specifications, had no master manufacturing records or batch production records, and did not set specifications for product received from suppliers. The website review found claims that the products treat or prevent disease, such as lowering cholesterol, lowering blood pressure, and treating prostate problems and hair loss.
What FDA found
The company set no finished-product specifications for identity, purity, strength, and composition of its He Shou Wu, DHT Blocker, Cordyceps, or Maitake Mushroom supplements, and its FTIR test cannot identify ingredients in products with more than one ingredient.
21 CFR 111.70(e)The company set no specifications to confirm that supplement material bought from a supplier was correctly identified and matched the purchase order, and its records used conflicting item codes and no lot number.
21 CFR 111.70(f)The company had no master manufacturing record, the written recipe and instructions for a product, and the one it later sent FDA was missing strength and batch size, theoretical yield, label description, sampling procedures, and process control steps.
21 CFR 111.205(a); 21 CFR 111.210The company wrote no batch production record for any batch it made; the example it sent FDA lacked equipment identity, cleaning dates, finished-product test results, packaging quantity, and records of the packaging and labeling steps.
21 CFR 111.255(a); 21 CFR 111.260Website claims that the products cure, treat, or prevent disease, such as lowering cholesterol or blood pressure and treating prostate problems, make them unapproved new drugs that FDA has not cleared as safe and effective.
21 U.S.C. 321(g)(1)(B); 21 U.S.C. 355(a)Schizandra Berry extract and DHT Blocker are sold for conditions a layperson cannot diagnose or treat alone, so they carry no adequate directions for use and are misbranded.
21 U.S.C. 352(f)(1)
What FDA wants
FDA asks the company to write back within 15 working days describing each step taken to fix the violations and prevent them recurring, with supporting documents. If fixes cannot be finished in that time, the company must explain why and give a completion date.
Who should pay attention
- brands that buy finished supplements from small contract manufacturers
- retailers and online marketplaces listing herbal supplement brands
- supplement makers that rely on FTIR alone to identify incoming ingredients
This is a summary. Read the original letter on fda.gov.